Do tirzepatide and semaglutide stop working over time?
Not in trials so far. People who stayed on tirzepatide (Mounjaro, Zepbound) or semaglutide 2.4 mg (Wegovy) for 2 to 4 years were still well below their starting weight at the end. Loss slowed and then levelled off. The US Zepbound label says the early slowing of the stomach fades. Weight came back when people stopped.
Do they keep working in long trials?
In trials lasting 2 to 4 years, people who stayed on either medicine were still well below their starting weight at the end.3,4,5
A 3-year tirzepatide trial followed 1,032 adults with obesity and prediabetes (blood sugar above normal but below the diabetes range). At 176 weeks, average loss was 12.3% on 5 mg, 18.7% on 10 mg and 19.7% on 15 mg. On a placebo (dummy injection) it was 1.3%.3
In the 2-year STEP 5 trial, average loss on semaglutide 2.4 mg was 15.2% at week 104, against 2.6% on placebo.4 SELECT, a heart trial, included 17,604 adults with heart disease and overweight or obesity, but no diabetes. Average loss on semaglutide was 10.2% at 4 years, against 1.5%. The authors say loss continued over 65 weeks and was sustained for up to 4 years.5
These results came with side effects. In STEP 5, 82.2% on semaglutide had stomach or bowel side effects, against 53.9% on placebo, mostly mild to moderate.4 In the tirzepatide trial, they were mostly mild to moderate and came mainly in the first 20 weeks, while the dose was going up.3 Our side effects guide covers the risks.
Why can it feel weaker after a few months?
The early slowing of the stomach eases with time, and in trials weight loss was fastest in the first months, then slowed.1,7
The US Zepbound label says tirzepatide delays stomach emptying most after the first dose, and that this effect diminishes over time.1
In one Zepbound trial, people lost 20.9% in the first 36 weeks. Those who stayed on it lost another 5.5% over the next 52 weeks.1 In the STEP 4 trial, people lost 10.6% in the first 20 weeks on semaglutide, then another 7.9% over the next 48.7 Slower loss later on is what the long trials show while the weight stays off.5
Some people do regain while still taking the medicine. A US health-records study by Epic Research followed 25,213 adults without diabetes who stayed on treatment for at least a year. By 2 years, about 8% on tirzepatide and 14.9% on semaglutide had regained at least a quarter of their first-year loss. It was not a clinical trial, and it only followed people still taking the medicine.6
What happens if the dose changes or you stop?
Both US labels say to weigh how well the medicine works, and how well it is tolerated, when choosing the long-term dose.1,2
Zepbound’s maintenance doses are 5 mg, 10 mg or 15 mg a week, and 15 mg is the maximum.1 The US Wegovy label allows a rise from 2.4 mg to a maximum of 7.2 mg a week. This applies to people who have tolerated 2.4 mg for at least 4 weeks and need more weight reduction.2
Stopping brought weight back. In the Zepbound trial above, people switched to placebo regained 14.0% of their weight over 52 weeks.1 In STEP 4, people switched to placebo regained 6.9% over 48 weeks.7
A lower dose kept part of the effect. In the SURMOUNT-MAINTAIN trial, people who stayed on their highest tolerated tirzepatide dose were 21.9% below their starting weight at 112 weeks. Those cut to 5 mg were 16.6% below, and those switched to placebo 9.9% below. The trial allowed rescue tirzepatide after large regain.8
What do people on GLP-1 medicines report about them wearing off?
From public patient forums: 59 Reddit threads in r/WegovyWeightLoss, r/Zepbound, r/Mounjaro, r/Ozempic, r/mounjarouk and r/WegovyPillWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the label Many say fullness and appetite control weakened after some months, often on a steady dose. The US Zepbound label says its slowing of the stomach is largest after the first dose and lessens over time.1
- Matches the label Many say loss slowed and levelled off, and see this as expected rather than the medicine failing. In a US Zepbound label trial, loss after the first 36 weeks was much slower.1
- Matches a study Many describe weight creeping back while still on the medicine, and some admit they had stopped tracking food. In a US records study, a minority on treatment regained a quarter of their loss by 2 years.6
- Matches the trial Many report holding their loss for years on continued treatment. In SELECT, average loss was sustained for up to 4 years.5
Advice people share
- Matches the label Many suggest restarting food tracking at the first sign of regain. Both US labels pair the medicine with a reduced-calorie diet and more activity.1,2
- Matches the label Many suggest asking the prescriber about a higher dose. The US labels go up to 15 mg for Zepbound and 7.2 mg for Wegovy, chosen on response and tolerability.1,2
- Label says otherwise Many describe self-directed breaks to “reset” the response, and several replies said this did not work. In a US Zepbound label trial, people switched to placebo regained 14.0% of their weight over 52 weeks.1
- Label says otherwise Many describe injecting more often than weekly or splitting doses. The US Zepbound label sets one injection a week, at least 3 days apart if the day changes, with 15 mg the maximum.1
In your country
The trials are the same everywhere, but the labels differ on the highest semaglutide dose, and the UK adds a check on whether to continue.9,10,11,12,13
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Wegovy Product Information allows 7.2 mg a week, given as 3 injections of 2.4 mg, only for adults whose BMI was 30 or more at the start, after at least 4 weeks on 2.4 mg. If weight does not improve further, the dose goes back to 2.4 mg.12
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The Canadian Wegovy monograph sets 2.4 mg a week as the maintenance dose and lists no 7.2 mg dose.13 For tirzepatide, the answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU Wegovy product information allows 7.2 mg a week only for adults whose BMI was 30 or more at the start, after at least 4 weeks on 2.4 mg. If weight does not improve further, the dose goes back to 2.4 mg.9
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU Wegovy product information allows 7.2 mg a week only for adults whose BMI was 30 or more at the start, after at least 4 weeks on 2.4 mg. If weight does not improve further, the dose goes back to 2.4 mg.9
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label for this page, so this answer relies on the US labels.1,2
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label for this page, so this answer relies on the US labels.1,2
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label for this page, so this answer relies on the US labels.1,2
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK SmPCs add a 5% check for weight management. On Mounjaro, it comes 6 months after reaching the highest tolerated dose. On Wegovy, it comes after 6 months of treatment. Anyone who has not lost at least 5% of their starting weight by then needs a decision on continuing.10,11 The UK Wegovy SmPC allows 7.2 mg a week for obesity after at least 4 weeks on 2.4 mg.11
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have severe stomach pain that will not go away, with or without vomiting, sometimes felt in your back. The US Zepbound label lists it as a sign of pancreatitis (an inflamed pancreas).1
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly (sections 2.1, 2.2, 2.3, 2.4, 12.2, 14 Study 4 and Table 6). uspl.lilly.com
- US Wegovy (semaglutide) prescribing information, Novo Nordisk, on DailyMed (sections 2.1, 2.2). dailymed.nlm.nih.gov
- Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-year results). N Engl J Med 2025;392:958–71. doi.org
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083–91. doi.org
- Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024;30:2049–57. doi.org
- Epic Research. Most Adults Without Diabetes Maintain Their GLP-1 Weight Loss Through a Second Year, Though Gradual Regain Begins After the One-Year Mark. 13 Aug 2026. epicresearch.org
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021. doi.org
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026. doi.org
- EU Wegovy (semaglutide) product information (SmPC section 4.2), European Medicines Agency. ema.europa.eu
- UK Mounjaro KwikPen (tirzepatide) SmPC, section 4.2, electronic Medicines Compendium. medicines.org.uk
- UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC, section 4.2, electronic Medicines Compendium. medicines.org.uk
- Australian Wegovy (semaglutide) Product Information, section 4.2. medsinfo.com.au
- Canadian Wegovy (semaglutide injection) Product Monograph, Health Canada Drug Product Database. pdf.hres.ca
- American College of Emergency Physicians. Know When to Go to the ER. emergencyphysicians.org
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write